Bringing Equity and Efficacy Together in Triple-Negative Breast Cancer: A Practical Guide for the Oncology Nurse
This Oncology Nursing Society (ONS) Chapter initiative is targeted to oncology nurses and nurse practitioners, specifically those practicing in the southeastern United States. Strategically designed to foster an understanding of both the disease state complexity and far-reaching racial disparity intrinsic to triple-negative breast cancer (TNBC), this educational session will begin with an appraisal of TNBC pathophysiology and the multifaceted etiologies of the disparate outcomes seen among African-American patients. Expert faculty will then guide attendees through a real-world exploration of antibody-drug conjugates, including structure, mechanism of action, and a dedicated focus on the effective anticipation, recognition, and mitigation of adverse events. Finally, attendees will take part in an interactive case-based discussion centered on how the oncology nurse can provision patient-centric care that is both efficacious and equitable through the incorporation of novel therapeutic approaches and the adoption of renewed perspectives.
Oncology Nurse Specialists, Registered Nurses, Nurse Practitioners
- Discuss the multifaceted etiology of the racial disparity observed in triple-negative breast cancer (TNBC), with a focus on both biologic and non-biologic factors, and identify tangible strategies oncology nurses can employ to promote equitable care and outcomes for all patients.
- Review antibody-drug conjugate (ADC) structure, mechanism of action, and real-world clinical considerations, with a particular focus on toxicity management, for oncology nurses who care for TNBC patients receiving ADCs.
- Examine completed, ongoing, and planned clinical trial data for ADCs as part of the expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
- Using a patient case-driven approach, design evidence-based treatment plans for patients with TNBC, with an emphasis on the placement of novel therapies in the shifting TNBC treatment calculus, strategies for anticipating, recognizing, and treating adverse events, and effectively integrating socioeconomic and other non-biologic factors into equitable cancer care.
Supported through an independent educational grant from Gilead.
Presented by Creative Educational Concepts, LLC.
5 min Welcome and Introductions/Pre-test
15 min Delineating the Disparity in TNBC: A Renewed Outlook on an Established Problem
20 min Demystifying Antibody-Drug Conjugates: The Role of the Oncology Nurse in the Evolving TNBC
15 min Closing the TNBC Outcomes Chasm: Nursing Perspectives on Novel Therapeutics and Patient-
5 min Conversations with the Experts/Audience Q&A/Post-test
Elahe Salehi, DNP, ANP-BC
Nurse Practitioner, Department of Breast Oncology
Director of Advanced Practice Nursing, Division of Women’s Cancers
Dana-Farber Cancer Institute
Elahe Salehi, DNP, ANP-BC, is currently working as an oncology nurse practitioner for Department of Breast Oncology. Her research focuses on improving the experience and safety of receiving cancer-directed therapies, with a focus on reducing toxicity and improving quality of life. She has designed and implemented Scalp Cooling Best Practice Guidelines and Policies at DFCI and is the Principal Investigator of DFHCC trial 21-169 (Assessing the Impact of Scalp Cooling in Patients with Metastatic Breast Cancer). Elahe Salehi began her nursing career in inpatient oncology, where she developed a passion for all oncology patients. She continued her career in the ambulatory oncology settings; for the last 12 years, her focus has been providing care to breast cancer patients from initial diagnosis through end-of-life care. She was honoured by one of her young breast cancer patients by inclusion in the 2017 Salute to Nurses in The Boston Globe. She is the recipient of the 2019 Dana-Farber President’s Award for Nursing Excellence, presented by the DFCI Nursing and Patient Care Services Department. Elahe Salehi received her Bachelor of Science in Nursing at Ryerson University in 2002, MSN-NP Adult Oncology at the Yale School of Nursing in 2006, and Doctor of Nursing Practice at MGH Institution of Health Professions in 2019. She is board certified as a nurse practitioner through the American Nurses Credentialing Center.
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Jennifer A. McKenna, NP–has no relevant financial relationships to disclose in relation to the content of this activity.
Elahe Salehi, DNP, ANP-BC–has no relevant financial relationships to disclose in relation to the content of this activity.
Lauren Olalde, RN–is on the speakers' bureau for Trodelvy.
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is designated for 1.0 contact hour.
ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, CBCN®, and CPHON® nurses may apply 1.0 point in Care Continuum, Coordination of Care, Diagnosis and Staging, Nursing Practice, Oncology Nursing Practice, Psychosocial Dimensions of Care, Symptom Management, and Treatment categories.
Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC.
- 1.00 ANCC
- 1.00 Participation